EcoR1 Capital’s Keros Therapeutics KROS Stock Holding History

EcoR1 Capital’s Portfolio KROS Stock Details KROS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-187,500	Closed	-$1.91M	–	43
2025 Q1	$1.91M	Hold	187,500	–	–	0.11%	35
2024 Q4	$2.97M	Hold	187,500	–	–	0.11%	47
2024 Q3	$10.9M	Hold	187,500	–	–	0.37%	41
2024 Q2	$8.57M	Hold	187,500	–	–	0.26%	42
2024 Q1	$12.4M	Buy	+187,500	New	+$11.1M	0.31%	41
2020 Q3	–	Sell	-220,216	Closed	-$8.26M	–	58
2020 Q2	$8.26M	Buy	+220,216	New	+$6.78M	0.61%	29

Other funds holding KROS

ACM

ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

MAP

Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

WSL

Western Standard LLC Los Angeles, California $295M AUM 40.98% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

EcoR1 Capital's KROS Position: Q2 2025 in Review

EcoR1 Capital sold out of Keros Therapeutics (KROS) in Q2 2025, closing a stake of 187,500 shares — an estimated $1.91M sold.

EcoR1 Capital first reported a position in KROS in Q2 2020 and held it in 6 quarters. The position peaked at $12.4M in Q1 2024. 139 funds tracked by Wall St. Rank hold KROS as of Q2 2025.

EcoR1 Capital reported no remaining Keros Therapeutics position as of Q2 2025 after selling out during the quarter.
EcoR1 Capital sold 187,500 Keros Therapeutics shares in Q2 2025, an estimated $1.91M.
EcoR1 Capital first reported a position in Keros Therapeutics in Q2 2020 and held it in 6 quarters.
EcoR1 Capital's Keros Therapeutics position peaked at $12.4M in Q1 2024.
139 funds tracked by Wall St. Rank held Keros Therapeutics as of Q2 2025.

Based on EcoR1 Capital's 13F filing for Q2 2025, filed 14 Aug 2025.